Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Imipramine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 13/20 | 0.97 |
| ▸ | SLC6A2 known ✓ | P23975 | 5/20 | 0.97 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | HRH1 | P35367 | 6/20 | 0.97 |
| ▸ | HTR2A | P28223 | 5/20 | 0.97 |
| ▸ | SLC22A1 | O15245 | 4/20 | 0.97 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.97 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.97 |
| ▸ | DRD2 | P14416 | 4/20 | 0.97 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.97 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.97 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.97 |
| ▸ | HTR2C | P28335 | 4/20 | 0.97 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.97 |
| ▸ | DRD3 | P35462 | 4/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Imipramine SCHEMBL41766 | 1.00 | LMNA (1.00) | LMNAMAPTPMP22SMN1; SMN2KDM4E | |
| Imipramine SCHEMBL28759733 | 1.00 | LMNA (1.00) | LMNAMAPTPMP22SMN1; SMN2KDM4E | |
| Imipramine SCHEMBL15719828 | 0.98 | LMNA (0.97) | LMNAMAPTPMP22SMN1; SMN2KDM4E | |
| Imipramine SCHEMBL34282 | 0.98 | SLC6A4 (1.00) | LMNAMAPTPMP22SMN1; SMN2KDM4E | |
| Imipramine SCHEMBL17004048 | 0.98 | SLC6A4 (1.00) | LMNAMAPTPMP22SMN1; SMN2KDM4E | |
| Imipramine SCHEMBL29350100 | 0.98 | SLC6A4 (1.00) | LMNAMAPTPMP22SMN1; SMN2KDM4E | |
| Imipramine SCHEMBL6118138 | 0.98 | SLC6A4 (1.00) | LMNAMAPTPMP22SMN1; SMN2KDM4E | |
| Imipramine SCHEMBL29040915 | 0.97 | SLC6A4 (0.97) | LMNAMAPTPMP22SMN1; SMN2KDM4E | |
| Imipramine SCHEMBL27657924 | 0.97 | SLC6A4 (0.97) | LMNAMAPTPMP22SMN1; SMN2KDM4E | |
| Imipramine SCHEMBL3002670 | 0.95 | SLC6A4 (0.94) | LMNAMAPTPMP22SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4267 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| EP-3357945-B1 | ADHESIVE POLYMER AND MEDICAL ADHESIVE PATCH | TEIKOKU SEIYAKU KK (JP) | 2024-10-30 | — | — | EP | claimed |
| EP-4297868-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | Hoth Therapeutics, Inc. (US) | 2024-01-03 | — | — | EP | claimed |
| US-11773098-B2 | Solid forms of a toll-like receptor modulator | GILEAD SCIENCES, INC. (US) | 2023-10-03 | — | — | US | claimed |
| US-20230285405-A1 | Pharmaceuticals for Treating or Preventing Nidoviruses and Picornaviruses | THE UNIVERSITY OF CHICAGO (US) | 2023-09-14 | — | — | US | claimed |
| US-20230248737-A1 | COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC DISORDERS OR SYMPTOMS THEREOF | PSYRX LTD. (IL) | 2023-08-10 | — | — | US | claimed |
| EP-4175643-A1 | COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC DISORDERS OR SYMPTOMS THEREOF | Psyrx Ltd. (IL) | 2023-05-10 | — | — | EP | claimed |
| US-20230123601-A1 | PHARMACEUTICAL COMBINATION OF ANTIVIRAL AGENTS TARGETING HBV AND/OR AN IMMUNE MODULATOR FOR TREATMENT OF HBV | HOFFMANN-LA ROCHE INC. | 2023-04-20 | — | — | US | claimed |
| US-20230003721-A1 | MITOTHERAPEUTICS FOR THE TREATMENT OF BRAIN DISORDERS | THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2023-01-05 | — | — | US | claimed |
| EP-4081217-A1 | PHARMACEUTICAL COMBINATION OF ANTIVIRAL AGENTS TARGETING HBV AND/OR AN IMMUNE MODULATOR FOR TREATMENT OF HBV | F. Hoffmann-La Roche AG (CH) | 2022-11-02 | — | — | EP | claimed |
| EP-0741570-A1 | METHOD FOR PREVENTING OR REDUCING PHOTOSENSITIVITY AND/OR PHOTOTOXICITY REACTIONS TO MEDICATIONS | G.D. SEARLE & CO. (US) | 1996-11-13 | — | — | EP | claimed |
| US-5563014-A | SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT | XEROX CORPORATION (US) | 1996-10-08 | — | — | US | claimed |
| US-5514505-A | SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE | XEROX CORPORATION (US) | 1996-05-07 | — | — | US | claimed |
| WO-1995029674-A1 | A METHOD OF MODIFYING ANGIOTENSIN RECEPTOR ACTIVITY FOR TREATMENT OF PREMENSTRUAL SYNDROME AND MEDIATION OF PAIN | DEPADOVA ANTHONY S (US) | 1995-11-09 | — | — | WO | claimed |
| WO-1995020387-A1 | METHOD FOR PREVENTING OR REDUCING PHOTOSENSITIVITY AND/OR PHOTOTOXICITY REACTIONS TO MEDICATIONS | G.D. SEARLE & CO. (US) | 1995-08-03 | — | — | WO | claimed |
| US-4977145-A | ADMINISTERING ANGIOTENSIN CONVERTING ENZYME INHIBITOR AND ANTIDEPRESSANT | E. R. SQUIBB & SONS, INC. (US) | 1990-12-11 | — | — | US | claimed |
| EP-0189861-A2 | Percutaneous absorption accelerator for ionic water-soluble medicine | SHOWA DENKO KABUSHIKI KAISHA (JP) | 1986-08-06 | — | — | EP | claimed |
| US-4505909-A | Method and composition for treating and preventing irritation of the eyes | BERNSTEIN JOEL E (US) | 1985-03-19 | — | — | US | claimed |
| US-4370324-A | Method and composition for treating and preventing irritation of the eyes | BERNSTEIN JOEL E (US) | 1983-01-25 | — | — | US | claimed |
| EP-0048023-A2 | Composition for treating and preventing irritation of the eyes | Bernstein, Joel E., M.D. (US) | 1982-03-24 | — | — | EP | claimed |